#ORPH Open Orphan – Imutex Vaccine Phase I Study Results
AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results Results to be presented at the American Society of Tropical Medicine and Hygiene Annual Meeting Open Orphan plc (AIM: ORPH) announces that data from the first-in-human Phase I clinical study evaluating the safety, immunogenicity, and in vitro efficacy of AGS-v PLUS, Imutex Limited’s (“Imutex’) mosquito saliva […]
#POLB Poolbeg Pharma – Update on POLB 001 Clinical Development
18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza. The Company intends to […]
#ORPH Open Orphan – £1.5m Contract renewal for Venn Life Sciences
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years. The renewed contract will commence in January 2022, with […]
Alan Green talks about #DEST Destiny Pharma, #BIDS Bidstack & #BRES Blencowe Resources
Alan Green talks about #DEST Destiny Pharma, #BIDS Bidstack & #BRES Blencowe Resources Listen to the Podcast – https://www.voxmarkets.co.uk/articles/alan-green-talks-about-destiny-pharma-bidstack-blencowe-resources-8eb524a/
#ORPH Open Orphan – Inside the quarantine lab where Irish company infects humans with Covid
Step into the foyer of the Whitechapel Hotel in London and it seems no different from any other business. But venture further in, and it becomes clear that something very strange is going on in this former textile factory. Biohazard signs on each floor warn observers not to enter. Next to the double beds […]
#POLB Poolbeg Pharma – PredictViral™ Patent update
4 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new patent filings for its PredictViral™ platform that estimates disease severity and contagiousness in people who are recently infected with a respiratory virus. Expanding on existing […]